ATE447417T1 - Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie - Google Patents

Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Info

Publication number
ATE447417T1
ATE447417T1 AT05722089T AT05722089T ATE447417T1 AT E447417 T1 ATE447417 T1 AT E447417T1 AT 05722089 T AT05722089 T AT 05722089T AT 05722089 T AT05722089 T AT 05722089T AT E447417 T1 ATE447417 T1 AT E447417T1
Authority
AT
Austria
Prior art keywords
denotes
analogas
angiotensin
conjugates
peptide
Prior art date
Application number
AT05722089T
Other languages
English (en)
Inventor
Dagfinn Lovhaug
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE447417T1 publication Critical patent/ATE447417T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05722089T 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie ATE447417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20040953 2004-03-04
PCT/NO2005/000078 WO2005084715A2 (en) 2004-03-04 2005-03-03 Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy

Publications (1)

Publication Number Publication Date
ATE447417T1 true ATE447417T1 (de) 2009-11-15

Family

ID=34918859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722089T ATE447417T1 (de) 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Country Status (7)

Country Link
US (1) US7763234B2 (de)
EP (1) EP1729823B1 (de)
JP (1) JP2007526300A (de)
CN (1) CN1925876A (de)
AT (1) ATE447417T1 (de)
DE (1) DE602005017475D1 (de)
WO (1) WO2005084715A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
EP1796733A2 (de) * 2004-09-29 2007-06-20 GE Healthcare AS Auf upar gezielte kontrastmittel
DE602005025911D1 (de) * 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
WO2010089757A2 (en) * 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
US9730916B2 (en) * 2014-02-27 2017-08-15 Chang Gung Memorial Hospital, Keelung Nutritional composition and method for improving heart failure
EP3759121A1 (de) 2018-03-01 2021-01-06 Trigemina, Inc. Markiertes oxytocin und verfahren zur herstellung und verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966896A (en) * 1974-09-06 1976-06-29 Mallinckrodt, Inc. Radioimmunoassay for plasma renin activity
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
CA2127284C (en) 1992-01-03 2002-02-05 Buck A. Rhodes Protein- and peptide-metal ion pharmaceutical applications
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
DE69735901T2 (de) 1996-10-28 2007-05-10 Ge Healthcare As Verbesseringen an oder in verbindung mit diagnostischen/therapeutischen mitteln
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
CA2405469C (en) 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
AU2001288847A1 (en) 2000-09-07 2002-03-22 Biosyntema Inc. Conformationally constrained labeled peptides for imaging and therapy
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
WO2005044313A2 (en) 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety

Also Published As

Publication number Publication date
WO2005084715A2 (en) 2005-09-15
US20070297979A1 (en) 2007-12-27
EP1729823B1 (de) 2009-11-04
CN1925876A (zh) 2007-03-07
EP1729823A2 (de) 2006-12-13
US7763234B2 (en) 2010-07-27
DE602005017475D1 (de) 2009-12-17
JP2007526300A (ja) 2007-09-13
WO2005084715A3 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
ZA200701280B (en) MR imaging method for the discrimination between healthy and tumour tissue
NO20064011L (no) Kontrastmidler for myokardial perfusjonsbilleddannelse
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
GB0326546D0 (en) Inhibitor imaging agents
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
DK1272507T3 (da) Integrinbindende peptidderivater
BRPI0416628A (pt) uso de compostos orgánicos
DE60213771D1 (en) Morpholinobildgebung und therapie
DE50209802D1 (de) Naht-set für medizinische zwecke
EP1778351A4 (de) Verifizierung von läsionsmerkmalen mit strahlformen
NO20072120L (no) Enzyme Inhibitor Imaging Agents
MA28153A1 (fr) Acides nucléiques se liant spécifiquement à la ghréline biologiquement active
ATE447417T1 (de) Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
AU2002328981A1 (en) Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri)
ATE272074T1 (de) An neuropeptide gebundenes rgd (arg-gly-asp)
WO2005053752A3 (en) Novel imaging agents comprising caspase-3 inhibitors
ATE425770T1 (de) Kontrastmittel
ATE289612T1 (de) Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
MA27772A1 (fr) Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons
BR0007702A (pt) Método e kit de diagnóstico para diagnose de endometriose
EA202192551A1 (ru) Способы диагностики рака легких

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties